Bloodwork Before Starting AOD-9604

Why Baseline Bloodwork Matters for AOD-9604

AOD-9604 is a modified fragment of human growth hormone corresponding to amino acids 177-191, engineered to retain the lipolytic activity of hGH while discarding its effects on IGF-1, insulin resistance, and tissue growth. It drives fat metabolism through beta-3 adrenergic receptor pathways and direct stimulation of lipolysis in adipose tissue, without the anabolic or diabetogenic profile of full-length growth hormone. That separation is the entire pharmacological premise — and baseline bloodwork exists to verify it holds in your body. Because AOD-9604 has limited published human data relative to other peptides in this space, a conservative pre-protocol lab panel is not optional. It is the only way to establish a metabolic reference point against which to measure both efficacy and safety in a compound where the clinical evidence base is still developing.

What to Test Before Starting

Four markers form the core of the pre-AOD-9604 baseline, each targeting a metabolic axis the peptide is expected to influence or, critically, leave alone.

IGF-1 is the most important confirmatory draw. The defining claim of AOD-9604 is that it does not raise IGF-1 the way full-length growth hormone does. A baseline IGF-1 value establishes the reference against which that claim can be verified in your own biology. If IGF-1 is already elevated before starting, you may be dealing with endogenous GH excess or another condition that needs investigation before introducing a GH-derived fragment.

Fasting Glucose captures insulin sensitivity at baseline. While AOD-9604 is designed to avoid the glucose-elevating effects of hGH, the limited human trial data means this assumption deserves verification, not trust. A fasting glucose between 70 and 99 mg/dL provides clearance. Values at or above 100 mg/dL warrant additional evaluation before starting a peptide that acts on fat metabolism pathways adjacent to glucose regulation.

Lipid Panel establishes your cholesterol and lipoprotein baseline before introducing a compound that directly promotes lipolysis. Total cholesterol, LDL, HDL, and the ratio between them will shift if AOD-9604 is mobilizing stored fat effectively. Without a pre-protocol lipid panel, those shifts have no context and no clinical meaning.

Body Weight should be recorded under standardized conditions — same time of day, same state of hydration — as a functional baseline that complements the serum markers. Body composition measurements, if available, add further resolution to what the lipid and metabolic panels capture in isolation.

What to Retest and When

At 8 weeks, retest body weight, visceral fat (if imaging or DEXA is available), and IGF-1. Body weight and visceral fat are the primary efficacy endpoints — if AOD-9604 is producing its expected lipolytic effect, measurable fat reduction should be evident by this point. IGF-1 at the same draw serves as the safety check: it should remain at baseline. Any rise in IGF-1 suggests the fragment is not behaving as cleanly as its pharmacological profile predicts and warrants a conversation with your provider.

At 12 weeks, retest triglycerides alongside a repeat lipid panel and fasting glucose. Triglycerides are expected to decrease as fat mobilization continues, and a 12-week interval provides enough time for sustained lipolytic activity to register in lipid metabolism. Fasting glucose at this draw confirms that insulin sensitivity has not deteriorated over the course of the protocol.

Discuss all results with your prescribing provider before continuing beyond the initial protocol period or adjusting dose.

Red Flags — When to Pause and Retest

Discontinue dosing and contact your provider if IGF-1 rises above the reference range, if fasting glucose exceeds 126 mg/dL, or if lipid values move in an unfavorable direction without explanation. Pregnancy, breastfeeding, and active malignancy are absolute contraindications — if any of these conditions are identified during monitoring, AOD-9604 must be stopped immediately. Concurrent use of exogenous growth hormone may compete for the same metabolic pathways and is not recommended. Given the limited human safety data, any unexpected lab movement should be treated conservatively.

How This Fits Your Broader Protocol

AOD-9604 is sometimes included in fat-loss or body-recomposition stacks alongside other metabolic peptides. If you are running a combination protocol, the same baseline panel applies, but IGF-1 monitoring becomes even more critical if other compounds in the stack influence the GH axis. Review the full contraindication profile before starting, and run any concurrent medications through the interaction checker to flag conflicts before your first dose.